Mold Allergy Shots: Evidence Gap Explained — Alternaria Yes, Others Limited
Mold allergy shots have a single well-controlled clinical-trial allergen — Alternaria alternata — and an evidence vacuum everywhere else. Kuna 2011 JACI documented 63.5% combined symptom-score reduction at Year 3 for Alternaria SCIT; Tabar 2019 confirmed efficacy with the major allergen Alt a 1. For Cladosporium, Aspergillus, and Penicillium, no DBPC-RCT evidence supports routine SCIT. Stachybotrys chartarum is NOT a SCIT indication.
6 peer-reviewed sources
Mold allergy shots are evidence-supported for Alternaria (Kuna 2011: 63.5% reduction at Year 3) but lack RCT evidence for most other molds. Stachybotrys chartarum SCIT is not indicated — remediation and medical evaluation are the appropriate steps.
The essentials
Mold allergy shots must be discussed with clinical honesty: within the mold allergen category, only Alternaria alternata has a published double-blind placebo-controlled SCIT RCT showing meaningful efficacy. The rest of the mold category — Cladosporium, Aspergillus, Penicillium, Stachybotrys — lacks RCT-level evidence, and the Cox 2011 PP3 explicitly cautions that mold extracts as a class are problematic: most are non-standardized, many contain proteases that degrade other allergens in multi-allergen vials, and lot-to-lot potency varies substantially.
Curex's at-home IgE testing distinguishes Alternaria sensitization — which has a published SCIT evidence base — from sensitization to molds like Cladosporium and Aspergillus where the immunotherapy data is thinner, with allergist review to interpret what is clinically actionable.
Alternaria alternata is the outdoor mold with the cleanest immunotherapy data. Kuna 2011 JACI (n=50 children, DBPC RCT) documented 38.7% combined symptom-score reduction at Year 2 and 63.5% reduction at Year 3 versus placebo, with reduced medication use. Tabar 2019 JACI confirmed efficacy and safety using the major allergen Alt a 1-standardized formulation. Alternaria sensitization is prevalent: NHANES 2005-2006 (Salo PM et al., JACI 2014;134:350-359) documented Alternaria-specific IgE positivity in approximately 13% of the US population ≥6 years. Outdoor mold spore season peaks late summer and fall in temperate US, overlapping with ragweed season and complicating symptom attribution — spore counts can reach 10,000–50,000 per cubic meter in agricultural regions during harvest.
For molds other than Alternaria, the honest clinical framing is extrapolation: SCIT practitioners treating Cladosporium or Aspergillus sensitization are doing so by analogy from Alternaria data. There are no DBPC RCTs for Cladosporium, Aspergillus, or Penicillium SCIT. Patients deserve this disclosure when considering whether a 3–5 year injection course is warranted for these sensitizations.
Stachybotrys chartarum — the "black mold" of media coverage — is a critical disambiguation. Stachybotrys SCIT is NOT indicated, and this distinction has clinical consequences. Stachybotrys exposure concerns center on mycotoxins (trichothecene group) and spore-mediated irritation, not IgE-mediated allergy. The appropriate pathway for Stachybotrys exposure concerns is environmental remediation, occupational medicine evaluation, and ruling out non-IgE granulomatous conditions such as hypersensitivity pneumonitis (HP). HP — caused by chronic inhalation of organic antigens including thermophilic actinomycetes and certain mold species — is a granulomatous lung disease with a non-IgE mechanism that SCIT does not treat. Indoor black mold remediation, not immunotherapy, is the correct intervention.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Efficacy by allergen — what the data shows
The mold category has a stark evidence divide: one well-characterized RCT allergen (Alternaria) and an evidence vacuum for the rest.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youSide effects — what to watch for
Mold SCIT carries the same general injection-site and systemic reaction profile as other SCIT allergens, with an additional caution: mold extracts contain proteases that can degrade adjacent allergens in mixed vials (Cox 2011 PP3), which is why many allergists separate mold extracts into a separate vial.
Frequently asked questions
Is there a mold allergy shot that actually works?
Yes, for Alternaria alternata specifically. Kuna 2011 (J Allergy Clin Immunol 2011;127:502-508) documented 38.7% combined symptom-score reduction at Year 2 and 63.5% at Year 3 in a double-blind, placebo-controlled RCT of 50 children receiving Alternaria SCIT. Tabar 2019 confirmed efficacy and safety using Alt a 1-standardized formulation. For Cladosporium, Aspergillus, Penicillium, and Stachybotrys, no comparable DBPC RCTs exist. Clinicians who include these molds in SCIT extract are doing so by extrapolation from Alternaria — a practice that should be disclosed to patients.
Should I get allergy shots for black mold exposure?
No. Stachybotrys chartarum — commonly called "black mold" — is not an indication for SCIT. Concerns about Stachybotrys exposure involve mycotoxins and spore-mediated irritation, not IgE-mediated allergy in the classical SCIT-treatable sense. The appropriate response to Stachybotrys exposure concerns is environmental remediation to remove the mold source, occupational medicine evaluation, and ruling out non-IgE hypersensitivity pneumonitis. There is no peer-reviewed mycotoxin-IgE-SCIT literature supporting immunotherapy for Stachybotrys exposure. Allergy shots will not protect against mycotoxin exposure.
What is hypersensitivity pneumonitis and is it treated with mold allergy shots?
Hypersensitivity pneumonitis (HP) — also called extrinsic allergic alveolitis — is a granulomatous interstitial lung disease caused by repeated inhalation of organic antigens, including certain mold species, thermophilic actinomycetes, and bird proteins. HP is mechanistically distinct from IgE-mediated mold allergy: it involves Type III (immune complex) and Type IV (T-cell-mediated granulomatous) immune reactions, not IgE and mast-cell degranulation. SCIT is NOT a treatment for HP. Management of HP involves identifying and removing the offending antigen exposure, corticosteroids in acute severe cases, and immunosuppression in chronic progressive forms. An IgE panel that is negative for mold-specific IgE does not rule out HP.
What molds can actually be treated with allergy shots?
Alternaria alternata is the only outdoor mold with a published double-blind placebo-controlled SCIT RCT demonstrating meaningful efficacy (Kuna 2011 JACI; Tabar 2019 JACI). FDA-standardized extracts for outdoor and indoor molds (other than via research formulations) are not among the 19 FDA-standardized US allergenic extracts — Alternaria and other molds are treated with non-standardized extracts, meaning lot-to-lot potency can vary (Cox 2011 PP3). Clinical practice extrapolates from Alternaria data to treat Cladosporium and Aspergillus sensitization, but this extrapolation has no direct RCT support. Patients with documented Alternaria sensitization and persistent seasonal mold-triggered AR or asthma are the most defensible candidates for mold SCIT.
Can mold allergy shots help with mold-triggered asthma?
Alternaria sensitization is a well-documented risk factor for severe mold-triggered asthma, particularly in inner-city children, and Alternaria SCIT is a reasonable candidate for asthma patients with documented Alternaria sensitization. The Kuna 2011 RCT included children with asthma and documented reduced medication use alongside symptom reduction. Cochrane Abramson 2010 (Cochrane Database Syst Rev 2010;CD001186) documented SCIT reducing asthma outcomes across multiple allergens, including mold allergens in the pooled data. Severe mold-allergic asthma — sometimes called the "thunderstorm asthma" phenotype associated with Alternaria spore episodes — may represent a particularly important indication for Alternaria SCIT.
What is the mold spore season in the United States?
Outdoor mold spore counts peak late summer and fall in temperate US regions — typically July through October, overlapping substantially with ragweed season and complicating symptom attribution. In agricultural regions during harvest, airborne Alternaria and Cladosporium spore counts can reach 10,000–50,000 per cubic meter. This overlap makes it clinically important to confirm which component — ragweed pollen or mold spores — is the dominant trigger via specific IgE testing before committing to an extract formulation. Indoor mold exposure from water damage is year-round and does not follow the outdoor spore calendar.
How do mold allergy shots compare to allergy shots for pollen or dust mite?
Pollen SCIT has the deepest evidence base (Cochrane Calderón 2007, 51 RCTs; Walker 2001 grass JACI; Creticos 1996 ragweed NEJM; Durham 1999 NEJM remission). Dust mite SCIT and SLIT tablet (Odactra, FDA-approved) are well-supported with standardized extracts (Der p, Der f). Mold SCIT — limited to Alternaria — has two confirming DBPC RCTs but a smaller patient base, non-standardized extracts with potency variability, and no FDA-approved SLIT tablet. For allergists building a mixed-allergen vial that includes Alternaria alongside pollen and dust mite extracts, a caution applies: mold proteases in the extract can degrade adjacent allergens in the same vial (Cox 2011 PP3), which is why separation into two vials is often recommended.
Related Articles
Allergy Vaccine: WHO Term for SCIT Explained | Curex
Allergy vaccine (WHO 1998) = allergen immunotherapy (SCIT/SLIT). No branded product — serums custom-compounded. At-home SCIT from Curex at $129/mo.
Read morePollen Allergy Shot: 3-Way Triage Guide | Curex
Pollen allergy shot triage: depot steroid (discouraged), SLIT tablet, or SCIT. Curex at-home SCIT is category 3: shots weekly at home, $129/month.
Read moreAllergy Shots vs Drops: Evidence-Based Comparison | Curex
Allergy shots (SCIT) vs sublingual drops (SLIT): comparable efficacy per Nelson 2015, but SLIT has zero fatalities vs 1 per 2.5M shots. Full comparison.
Read moreAllergy Shots for Seasonal Allergies | Curex Guide
Yes, allergy shots work for seasonal allergies — Cochrane 51 RCTs found symptom SMD −0.73. Learn who qualifies, what the commitment is, and what 23.9% dropout means.
Read moreAllergy Shots for Cats (Humans) | Curex SCIT Guide
Allergy shots for cats target Fel d 1 for HUMANS, not the pet. 23.9% quit conventional SCIT (Tkacz 2021). Curex delivers that SCIT at home, $129/mo.
Read moreAllergy Shots for Tree Pollen: Birch, Oak & Cedar | Curex
Tree SCIT: birch 40% reduction (Bødtger 2002), Bet v 1 / PR-10 cross-reactivity, OAS, cedar gap. Curex at-home shots cover birch, oak, cedar.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.